About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Leukemia Clinical Trials in Austin | 1,100 Studies | Clareo Health

Clinical Trials LeukemiaAustin

Leukemia Clinical Trials in Austin

Find 1,100 clinical trials for leukemia near Austin, Texas. Connect with research centers in your area.

All Leukemia trials nationwide All trials in Austin

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 941-960 of 1,100 trials

COMPLETEDPhase 3< 1 mile

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023

To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.

Seasonal Allergic Rhinitis

Sumitomo Pharma America, Inc.707 participantsStarted Nov 2008

Austin, Texas, United States • Kerrville, Texas, United States • New Braunfels, Texas, United States +1 more locations

TERMINATEDPhase 217 miles

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920

The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.

Multiple Sclerosis, Relapsing-RemittingClinically Isolated Syndrome

Opexa Therapeutics, Inc.116 participantsStarted Nov 2007

Cullman, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +24 more locations

Leukemia Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 317 miles

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484

The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".

Muscle WastingNon Small Cell Lung Cancer

GTx321 participantsStarted Jul 2011

Birmingham, Alabama, United States • Long Beach, California, United States • Aventura, Florida, United States +24 more locations

TERMINATEDPhase 362 miles

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

NCT00004933

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia that has not responded to interferon alfa. PURPOSE: Randomized phase III trial to compare the effectiveness of homoharringtonine with that of hydroxyurea in treating patients who have chronic myelogenous leukemia that has not responded to interferon alfa.

Alliance for Clinical Trials in Oncology5 participantsStarted Jan 2000

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +130 more locations

COMPLETEDPhase 262 miles

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

NCT01137968

The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.

Non-small Cell Lung Cancer

Geron Corporation116 participantsStarted May 2010

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Anaheim, California, United States +30 more locations

TERMINATEDPhase 374 miles

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT01798485

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.

Non-Small-Cell Lung AdenocarcinomaNon-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IV+1 more

Synta Pharmaceuticals Corp.696 participantsStarted Apr 2013

Flagstaff, Arizona, United States • Prescott Valley, Arizona, United States • Sedona, Arizona, United States +264 more locations

COMPLETEDNA74 miles

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

NCT00080873

RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation. PURPOSE: This randomized clinical trial is studying how well Traumeel® S works in preventing or treating mucositis in young patients who are receiving chemotherapy with or without total-body irradiation before undergoing stem cell transplantation.

Kidney CancerLeukemiaLymphoma+3 more

Children's Oncology Group195 participantsStarted Apr 2004

Birmingham, Alabama, United States • Los Angeles, California, United States • Orange, California, United States +41 more locations

COMPLETEDPhase 1147 miles

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

NCT01398462

CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1 and survivin.

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome+1 more

JW Pharmaceutical69 participantsStarted Jul 2011

Houston, Texas, United States • Seattle, Washington, United States • Seoul, South Korea +2 more locations

COMPLETEDNA147 miles

Blood and Marrow Transplant Clinical Research Network

NCT00023530

The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.

Bone Marrow TransplantationBlood DiseaseHematopoietic Stem Cell Transplantation+4 more

National Heart, Lung, and Blood Institute (NHLBI)Started Sep 2001

Duarte, California, United States • La Jolla, California, United States • Palo Alto, California, United States +13 more locations

COMPLETEDPhase 3147 miles

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294

The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.

Non-Small-Cell Lung Carcinoma

Eli Lilly and Company755 participantsStarted Dec 2004

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +121 more locations

COMPLETEDPhase 2182 miles

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

NCT01297491

The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous.

Non-small Cell Lung Cancer

Novartis Pharmaceuticals63 participantsStarted May 2011

Chandler, Arizona, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +89 more locations

COMPLETEDNA194 miles

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829

The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

Metastatic Breast CancerLocally Recurrent Breast Cancer

Sorrento Therapeutics, Inc.111 participantsStarted Mar 2014

Fayetteville, Arkansas, United States • Chattanooga, Tennessee, United States • Memphis, Tennessee, United States +17 more locations

COMPLETEDPhase 2360 miles

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT00671788

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Gynecologic Oncology Group35 participantsStarted Jun 2008

Hartford, Connecticut, United States • New Britain, Connecticut, United States • Sarasota, Florida, United States +17 more locations

COMPLETEDPhase 3419 miles

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

NCT00058331

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective than epoetin alfa given once every 3 weeks in treating anemia. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients who have solid tumors.

AnemiaLeukemiaLymphoma+4 more

Alliance for Clinical Trials in Oncology365 participantsStarted Jun 2003

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Peoria, Illinois, United States +15 more locations

COMPLETEDPhase 3451 miles

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

NCT00656136

This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed. The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up.

Carcinoma, Non-Small-Cell Lung

Boehringer Ingelheim585 participantsStarted Apr 2008

Kingman, Arizona, United States • Fayetteville, Arkansas, United States • Anaheim, California, United States +87 more locations

COMPLETEDPhase 2560 miles

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

NCT00003700

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.

Alliance for Clinical Trials in Oncology163 participantsStarted Jan 1999

Birmingham, Alabama, United States • La Jolla, California, United States • San Francisco, California, United States +47 more locations

COMPLETEDPhase 2560 miles

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

NCT00002494

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.

LeukemiaLymphoma

Alliance for Clinical Trials in Oncology134 participantsStarted May 1992

La Jolla, California, United States • San Francisco, California, United States • Wilmington, Delaware, United States +20 more locations

COMPLETED560 miles

Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia

NCT00003931

RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia.

Alliance for Clinical Trials in Oncology9,769 participantsStarted Feb 1999

Birmingham, Alabama, United States • La Jolla, California, United States • San Francisco, California, United States +43 more locations

COMPLETEDPhase 2753 miles

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181

The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of participants with relapsed or recurrent Small Cell Lung Cancer. This study also plans to find out what effects, good or bad (side effects), OSI-906 has on participants and or Small Cell Lung Cancer. The study will also investigate if some proteins measured in the blood or tumor and some imaging features obtained from computed tomography (CT) scans can help predict whether OSI-906 or topotecan will be effective against Small Cell Lung Cancer.

Recurrent Small Cell Lung Carcinoma

National Cancer Institute (NCI)44 participantsStarted Feb 2012

Scottsdale, Arizona, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +8 more locations

COMPLETEDPhase 2926 miles

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009

There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD. We are initiating this study of post-transplant fast withdrawal of immunosuppression and donor lymphocyte infusions, with a goal of achieving full donor chimerism in children with hematologic malignancies. If our hypothesis that full donor chimerism results in leukemia-free survival is correct, using immune modulation to achieve full donor chimerism should decrease relapse rate and thus increase survival. The goal of this Phase II study is to identify if achieving full donor chimerism in whole blood CD3+ and leukemia-specific (CD14/15+, CD19+, CD33+ and CD34+) subset may decrease the risk of relapse of patients undergoing allogeneic transplant for hematologic malignancy.

Acute LeukemiaAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia+7 more

University of California, San Francisco43 participantsStarted Oct 2009

San Francisco, California, United States • St. Petersburg, Florida, United States

PreviousPage 48 of 55Next

Other Conditions in Austin

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Lymphoma